-
Nullscript: A Context-First HDAC Research Guide
2026-09-11
Nullscript is a histone deacetylase inhibitor with an unusual separation between HDAC inhibition and transcriptional facilitation. This guide explains how to use that profile in cardiac ischemia/reperfusion studies and how a necroptosis-focused kidney study can sharpen assay design without overstating cross-domain evidence.
-
Nullscript: From HDAC Mechanism to Translational Strategy
2026-09-11
Nullscript offers translational researchers a way to study HDAC biology while separating enzyme inhibition from transcriptional facilitation. This thought-leadership article connects its reported cardioprotective activity with emerging metabolic stress biology, including the NMNAT3–NAD+–ferroptosis axis identified in placental nanoplastic toxicity, while defining practical boundaries for preclinical interpretation.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Precision Editing
2026-09-10
EZ Cap™ Cas9 mRNA (m1Ψ) provides a transient, translation-ready Cas9 input for CRISPR-Cas9 genome editing in mammalian cells. Its Cap1 structure, m1Ψ modification, and poly(A) tail support practical optimization of expression, RNA handling, and immune-response control while enabling experiments inspired by mRNA nuclear-export regulation.
-
Syringin: Mechanism-First RCC Assay Design
2026-09-10
Syringin natural product research is strengthened by a mechanism-first framework that connects viability, apoptosis, migration, combination response, and EGFR/PI3K/Akt signaling. This article translates the key RCC study into evidence-aware assay decisions while defining formulation, analytical, and translational limits.
-
Zoledronic Acid: Designing Translational Assays
2026-09-09
Zoledronic Acid research benefits from more than a viability endpoint. This guide connects apoptosis, protein kinase C signaling, bone-disease models, and causal assay design inspired by recent γδT17 research to improve mechanistic and translational interpretation.
-
Protease Inhibitor Cocktail: K4003 Guide
2026-09-09
This scenario-driven guide explains how Protease Inhibitor Cocktail (100X H₂O, EDTA Plus), SKU K4003, can reduce extraction-related variability in cell viability, proliferation, cytotoxicity, and lipid-droplet protein studies. It covers compatibility, dilution, EDTA limitations, interpretation, and practical supplier-selection criteria for reproducible laboratory workflows.
-
Adipose ANGPTL4 Controls Triglyceride Partitioning
2026-09-08
This study used adipocyte-specific Angptl4 knockout mice to separate the local role of adipose ANGPTL4 from effects of whole-body deficiency. The findings show that adipose ANGPTL4 strongly regulates triglyceride delivery under baseline conditions, but its influence becomes limited after prolonged high-fat feeding, when lipoprotein lipase is no longer the main constraint on adipocyte triglyceride uptake.
-
Protease Inhibitor Cocktail: EDTA-Free Workflow
2026-09-08
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolysis during cell lysis, protein extraction, and protease-sensitive downstream assays. It is intended for workflows that require broad protease coverage without EDTA, but it should not be treated as a universal substitute for sample-specific validation or as proof that every target protein will be preserved.
-
Protease Inhibitor Cocktail: MS-SAFE Guide
2026-09-07
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO), SKU K4001, helps limit endogenous proteolysis during cell and tissue protein extraction and is formulated without AEBSF for mass spectrometry workflows. It should be used with rapid cold handling and validated separately for metalloproteinases, phosphatase-sensitive endpoints, and assay-specific DMSO tolerance.
-
Vemurafenib (PLX4032) in Melanoma Research
2026-09-07
Vemurafenib, also called PLX4032 and RG7204, is a selective BRAF V600E inhibitor used to study MAPK signaling, melanoma cell proliferation inhibition, and resistance. The A3004 product combines a reported BRAF V600E IC50 of 31 nM with research applications spanning melanoma cell assays and Colo829 xenograft models.
-
Sumatriptan as an Anti-Inflammatory Agent: Review Insights
2026-09-05
This systematic review reframes sumatriptan as more than an acute antimigraine drug by synthesizing evidence for anti-inflammatory effects involving cytokines, nitric oxide signaling, caspases, and calcitonin gene-related peptide. Its main practical contribution is a mechanistic map linking 5-HT1B/1D receptor pharmacology with protection in diverse experimental injury and inflammation models, while also highlighting the limits of translating predominantly preclinical evidence.
-
Lipo3K Transfection Reagent for APOL1 Studies
2026-09-04
Build reproducible APOL1 isoform, variant, and APOL3-interaction assays with a low-toxicity lipid transfection reagent designed for DNA, siRNA, and mRNA delivery. Lipo3K supports difficult cell models, plasmid enhancement, and DNA and siRNA co-transfection while allowing direct collection for downstream analysis.
-
RNA m6A in Cucumber Mosaic Virus Defense
2026-09-04
The reference study identifies RNA m6A modification as a dynamic battleground between cucumber mosaic virus and its plant host. It shows that host writers and the ECT8 reader can mark and destabilize viral RNA, whereas the CMV 2b protein disrupts methyltransferase activity and reshapes host m6A patterns, providing a mechanistic framework for plant antiviral research.
-
Sodium Oxamate for LDH-A and Lactate Assays
2026-09-03
Sodium Oxamate provides a water-compatible way to perturb LDH-A activity, lactate production, and radioresistance workflows without relying on DMSO. This guide connects dose-response design with lactylation, DNA-repair, and TNBC assays inspired by a recent mechanistic study.
-
Phenothiazines, ROS, and Macrophage Autophagy
2026-09-03
Qiu et al. identify a host-directed antibacterial mechanism in which phenothiazines strengthen macrophage defense through reactive oxygen species accumulation, lysosomal activation, and autophagy. Pharmacological inhibition of these processes weakened the phenotype, while perphenazine reduced lesion and inflammatory outcomes in a Salmonella Typhimurium model, supporting phenothiazines as lead compounds for intracellular infection research.